Obtusilactone B from Machilus Thunbergii targets barrier-to-autointegration factor to treat cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Targeted cancer therapies utilize molecular inhibitors to exploit oncogene dependencies.
• Novel small-molecule inhibitors are crucial for addressing diverse cancer types and stages.
• Obtusilactone B, a butanolide derivative from Machilus thunbergii, is investigated for its therapeutic potential.

Purpose of the Study:

• To investigate obtusilactone B as a small-molecule inhibitor targeting cancer cell growth.
• To elucidate the mechanism of action of obtusilactone B involving nuclear envelope dynamics and BAF phosphorylation.
• To evaluate the potential of targeting barrier-to-autointegration factor (BAF) for cancer treatment.

Main Methods:

• Purification of obtusilactone B from Machilus thunbergii.
• Assay of obtusilactone B's inhibitory effects on cancer cell growth in vitro.
• Investigation of obtusilactone B's interaction with barrier-to-autointegration factor (BAF) and VRK1-mediated phosphorylation.
• Analysis of nuclear envelope dynamics and cell cycle progression.

Main Results:

• Obtusilactone B acts as a small-molecule inhibitor, inducing abnormal nuclear envelope dynamics.
• It suppresses vaccinia-related kinase 1 (VRK1)-mediated phosphorylation of barrier-to-autointegration factor (BAF).
• Suppression of BAF phosphorylation by obtusilactone B inhibits cell cycle progression and induces potent tumor cell death in vitro.

Conclusions:

• Targeting BAF to disrupt nuclear envelope integrity and block cell cycle progression is a viable anticancer strategy.
• Obtusilactone B demonstrates potential as a novel therapeutic agent for cancer treatment.
• Targeting nuclear envelope constituents represents a promising alternative approach in cancer therapy.